183 related articles for article (PubMed ID: 36876282)
1. Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients.
Pfrepper C; Koch E; Weise M; Siegemund R; Siegemund A; Petros S; Metze M
Res Pract Thromb Haemost; 2023 Feb; 7(2):100054. PubMed ID: 36876282
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
3. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring of tinzaparin in a ten day treatment dose in elderly patients].
Pautas E; Siguret V; d'Urso M; Laurent M; Gaussem P; Février M; Durand-Gasselin B
Rev Med Interne; 2001 Feb; 22(2):120-6. PubMed ID: 11234669
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
7. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers.
Holst J; Lindblad B; Bergqvist D; Garre K; Nielsen H; Hedner U; Ostergaard PB
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):795-803. PubMed ID: 7865687
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Norris LA; Bonnar J; Smith MP; Steer PJ; Savidge G
Thromb Haemost; 2004 Oct; 92(4):791-6. PubMed ID: 15467910
[TBL] [Abstract][Full Text] [Related]
9. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
[TBL] [Abstract][Full Text] [Related]
11. Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels.
Olie RH; Meertens NEL; Henskens YMC; Ten Cate H
Nephron; 2017; 137(2):113-123. PubMed ID: 28662505
[TBL] [Abstract][Full Text] [Related]
12. Extended thromboprophylaxis post gynaecological cancer surgery; the effect of weight adjusted and fixed dose LMWH (Tinzaparin).
Abu Saadeh F; Marchocki Z; O'Toole SA; Ibrahim N; Gleeson N; Norris LA
Thromb Res; 2021 Nov; 207():25-32. PubMed ID: 34530386
[TBL] [Abstract][Full Text] [Related]
13. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
[TBL] [Abstract][Full Text] [Related]
14. Higher Tinzaparin Dosing Is Needed to Achieve Target Anti-Xa Levels in Pediatric Cardiac Intensive Care Patients.
Roeleveld PP; van der Hoeven A; de Wilde RB; Eikenboom J; Smiers FJ; Bunker-Wiersma HE
Pediatr Crit Care Med; 2016 Mar; 17(3):203-9. PubMed ID: 26808621
[TBL] [Abstract][Full Text] [Related]
15. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
Hainer JW; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Leathers T; Leese PT
Thromb Haemost; 2002 May; 87(5):817-23. PubMed ID: 12038783
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
Jeske W; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence.
Christopoulou A; Ardavanis A; Papandreou C; Koumakis G; Papatsimpas G; Papakotoulas P; Tsoukalas N; Andreadis C; Samelis G; Papakostas P; Aravantinos G; Ziras N; Souggleri M; Kalofonos C; Samantas E; Makrantonakis P; Pentheroudakis G; Athanasiadis A; Stergiou H; Bokas A; Grivas A; Tripodaki ES; Varthalitis I; Timotheadou E; Boukovinas I
Oncol Lett; 2022 Apr; 23(4):115. PubMed ID: 35251346
[TBL] [Abstract][Full Text] [Related]
18. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation post elective caesarean section: effect of low molecular weight heparin.
Ismail SK; Norris L; Muttukrishna S; Higgins JR
Thromb Res; 2012 Nov; 130(5):799-803. PubMed ID: 22365560
[TBL] [Abstract][Full Text] [Related]
20. Laboratory analysis of blood samples from patients treated with tinzaparin.
Hoppensteadt DA; Willows L; Leitz H; Nicolaides A; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():49-55. PubMed ID: 15085466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
